Table 1.
Clinical and laboratory characteristics of 107 patients with interferon-induced type 1 diabetes mellitus n (%)
| Variable | Caucasian n = 20 | Japanese n = 87 |
| Age (range), yr | 43 (24-66) | 52 (45-63) |
| Males | 13 (65) | 48 (52) |
| HCV genotype | ||
| Type 1b | 1 (5) | 28 (32) |
| Non- type 1b | 7 (32) | 6 (7) |
| Unavailable data | 12 (63) | 53 (61) |
| Type of therapy | ||
| Non-Peg INF-α | 10 (50) | 39 (45) |
| Peg INF-α | 10 (50) | 45 (52) |
| Other types of INF | - | 3 (3) |
| Combination with ribavirin | 15 (75) | 54 (62) |
| Patients who developed DM during INF treatment | 17 (85) | 63 (72) |
| Patients who developed DM after INF cessation | 3 (15) | 24 (28) |
| Time-period between INF initiation and T1DM onset mo | 4.2 (1.8-8.5) | 5.7 (2.8-14.6) |
| Time-period between INF cessation and T1DM onset (mo) | 3.6 (3.0-4.0) | 6.3 (1.6-13) |
| Ab positive before INF treatment | 10 (62) | 0 (0) |
| Ab negative before INF treatment | 6 (38) | 4 (100) |
| Not done | 4 (20) | 83 (95.4) |
| Insulin therapy at end of follow-up | 20 (100) | 85 (98) |
HCV: Hepatitis C virus; Peg INF-α: Pegylated interferon α; T1DM: Type 1 diabetes mellitus.